Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64years, 2007-2011

Influenza and other Respiratory Viruses

Volumn 7, Issue 5, 2013, Pages 729-737

  Kelly, Heath A ^a,b   Sullivan, Sheena G ^c   Grant, Kristina A ^a   Fielding, James E ^a,b  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b The Australian National University   (Australia)

^c WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

Author keywords

Influenza; Influenza vaccine; Influenza like illness; Vaccine effectiveness

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

ADULT; ARTICLE; AUSTRALIA; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; GENERAL PRACTICE; GROUPS BY AGE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTECTION; VIRUS STRAIN;

INFLUENZA; INFLUENZA VACCINE; INFLUENZA-LIKE ILLNESS; VACCINE EFFECTIVENESS;

ADULT; AUSTRALIA; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SENTINEL SURVEILLANCE; YOUNG ADULT;

EID: 84882678919     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12018     Document Type: Article

References (32)

1. Barr IG, McCauley J, Cox N et al. Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season. Vaccine 2009; 28:1156-1167.
2. Last J, Porta M. A Dictionary of Epidemiology, 5th edn. New York, USA: Oxford University Press, 2008.
3. Kelly H, Barr I. Large trials confirm immunogenicity of H1N1 vaccines. Lancet 2009; 375:6-9.
4. Valenciano M, Kissling E, Cohen JM et al. Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med 2010; 8:e1000388.
5. Belongia EA, Kieke BA, Donahue JG et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159-167.
6. Skowronski DM, Masaro C, Kwindt TL et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842-2851.
7. Fielding JE, Grant KA, Papadakis G, Kelly HA. Estimation of type- and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008. BMC Infect Dis 2011; 11:170.
8. Kelly H, Carville K, Grant K, Jacoby P, Tran T, Barr I. Estimation of influenza vaccine effectiveness from routine surveillance data. PLoS ONE 2009; 4:e5079.
9. Orenstein EW, De Serres G, Haber MJ et al. Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol 2007; 36:623-631.
10. Victorian Infectious Diseases References Laboratory. The Victorian influenza vaccine effectiveness audit. Available at: https://www.victorianflusurveillance.com.au/ (Accessed 27 September 2012).
11. Thursky K, Cordova SP, Smith D, Kelly H. Working towards a simple case definition for influenza surveillance. J Clin Virol 2003; 27:170-179.
12. Kelly HA, Grant KA, Fielding JE et al. Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine 2011; 29:6419-6426.
13. Fielding JE, Grant KA, Garcia K, Kelly HA. Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 2011; 17:1181-1187.
14. Fielding J, Grant K, Tran T, Kelly H. Moderate influenza vaccine effectiveness in Victoria, Australia, 2011. Euro Surveill 2012; 17:pii=20115.
15. Druce JD, Tran T, Kelly H et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002-2003. J Med Virol 2005; 75:122-129.
16. Greenland S, Lash TL. Bias anaylsis; in Rothman KJ, Greenland S, Lash TL (eds): Modern Epidemiology. 3rd edn. Philadelphia: Lippincott, Williams & Wilkins, 2008;345-380.
17. Australian Government Department of Health and Ageing. Immunise Australia Program. Available at: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-influenza (Accessed 27 September 2012).
18. Looker C, Carville K, Grant K, Kelly H. Influenza A (H1N1) in Victoria, Australia: a community case series and analysis of household transmission. PLoS ONE 2010; 5:e13702.
19. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill 2009; 14:pii=19288.
20. Carrat F, Vergu E, Ferguson NM et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 2008; 167:775-785.
21. WHO Collaborating Centre for Reference and Research on Influenza. Current Vaccine Recommendations. Available at: http://www.influenzacentre.org/centre_vaccines.htm (Accessed 16 February 2012).
22. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 2011; 203:1309-1315.
23. CSL Limited. A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults. Available at: http://clinicaltrials.gov/ct2/show/NCT00562484?term=A+Study+of+the+Efficacy%2C+Safety+and+Tolerability+Profile+of+CSL+Limited%27s+Influenza+Virus+Vaccine&rank=1 (Accessed 27 September 2012).
24. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36-44.
25. Kissling E, Valenciano M, Cohen JM et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS ONE 2011; 6:e27622.
26. Ansaldi F, Bacilieri S, Amicizia D et al. Antigenic characterisation of influenza B virus with a new microneutralisation assay: comparison to haemagglutination and sequence analysis. J Med Virol 2004; 74:141-146.
27. Skowronski DM, Janjua NZ, De Serres G et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-11 Season. Clin Infect Dis 2012; 55:332-342.
28. Chan TC, Hsiao CK, Lee CC et al. The impact of matching vaccine strains and post-SARS public health efforts on reducing influenza-associated mortality among the elderly. PLoS ONE 2010; 5:e11317.
29. Belongia EA, Kieke BA, Donahue JG et al. Influenza vaccine effectiveness in Wisconsin during the 2007-2008 season: comparison of interim and final results. Vaccine 2011; 29:6558-6563.
30. Cheng AC, Kotsimbos T, Kelly HA et al. Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study. Vaccine 2011; 29:7320-7325.
31. Castilla J, Martinez-Artola V, Salcedo E et al. Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study. Vaccine 2012; 30:195-200.
32. Jimenez-Jorge S, Savulescu C, Pozo F et al. Effectiveness of the 2010-2011 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012; 30:24.